** Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 2% to $62.70
** Co says the U.S. FDA has given expanded approval for Iluvien to treat chronic, non-infectious uveitis affecting the posterior segment of the eye (NIU-PS)
** NIU-PS is characterized by inflammation of the retina or optic nerve of the eye
** Iluvien is already approved by the FDA to treat another eye condition called diabetic macular edema $(DME.AU)$
** Co plans to market Iluvien under the combined label in the U.S. later this year
** Up to last close, ANIP has fallen 7.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.